Core Viewpoint - The Gross Law Firm is notifying shareholders of Revance Therapeutics, Inc. about a class action lawsuit due to alleged misleading statements and material breaches related to a Distribution Agreement with Teoxane [1][2]. Group 1: Allegations - The complaint alleges that Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance exclusive rights to import, market, promote, sell, and distribute Teoxane's dermal fillers [1]. - The breach subjected the company to increased risks of litigation, monetary losses, and reputational harm [1]. - The allegations suggest that these issues increased the risk of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading [1]. Group 2: Class Action Details - The class period for the lawsuit is from February 29, 2024, to December 6, 2024 [1]. - Shareholders are encouraged to register for the class action by March 4, 2025, to potentially be appointed as lead plaintiffs [2]. - There is no cost or obligation for shareholders to participate in the case, and they will receive status updates through portfolio monitoring software [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Revance Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and material breaches related to a Distribution Agreement with Teoxane [1][2]. Allegations - The complaint alleges that Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance exclusive rights to import, market, promote, sell, and distribute Teoxane's dermal fillers [1]. - The breach subjected the company to increased risks of litigation, monetary losses, and reputational harm [1]. - The allegations suggest that these issues increased the risk of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading [1]. Class Action Details - The class period for the lawsuit is from February 29, 2024, to December 6, 2024 [1]. - Shareholders are encouraged to register for the class action by March 4, 2025, to potentially be appointed as lead plaintiffs [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm is committed to ensuring companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflate stock prices [3].

Core Points - A class action securities lawsuit has been filed against Revance Therapeutics, Inc. for alleged securities fraud affecting investors between February 29, 2024, and December 6, 2024 [1][2] - The lawsuit claims that Revance was in material breach of its Distribution Agreement with Teoxane, which granted exclusive rights to market and distribute Teoxane's dermal fillers, leading to increased litigation risks and potential harm [2] - Investors have until March 4, 2025, to request to be appointed as lead plaintiff, with no costs required to participate in the lawsuit [3] Company Details - Revance Therapeutics is facing allegations that its public statements were materially false and misleading, which could have significant implications for its reputation and financial standing [2] - The lawsuit highlights the potential for monetary and reputational harm due to the alleged breach of agreement with Teoxane [2] Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Revance Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and material breaches related to a Distribution Agreement with Teoxane [1][2]. Summary by Sections Allegations - The complaint alleges that Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance exclusive rights to import, market, promote, sell, and distribute Teoxane's dermal fillers [1]. - The breach subjected the company to increased risks of litigation, monetary losses, and reputational harm [1]. - These issues raised the risk of delays or amendments to a tender offer, making the company's public statements materially false and misleading throughout the relevant period [1]. Class Action Details - The class period for the lawsuit is from February 29, 2024, to December 6, 2024 [1]. - Shareholders are encouraged to register for the class action by March 4, 2025, to potentially be appointed as lead plaintiffs [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

Core Viewpoint - A federal securities class action has been filed against Revance Therapeutics, Inc. for alleged misleading statements and material breaches related to its distribution agreement and merger negotiations, with a deadline for investors to seek lead plaintiff status by March 4, 2025 [1][6]. Company Overview - Revance Therapeutics entered into a distribution agreement with Teoxane SA in January 2020, granting exclusive rights to market and sell Teoxane's dermal fillers in exchange for 2.5 million shares of Revance common stock [3]. - In August 2024, Revance announced a merger agreement with Crown Laboratories, with a tender offer to acquire Revance shares at $6.66 each, valuing the company at $924 million [3]. Recent Developments - On September 23, 2024, Revance disclosed a notice of alleged material breaches regarding its distribution agreement with Teoxane, leading to a delay in Crown's tender offer and a subsequent decline in Revance's share price by 7.66% [4]. - On December 9, 2024, Revance announced an amendment to the merger agreement, reducing the tender offer price to $3.10 per share, over 50% lower than the initial offer, causing a further decline in share price by approximately 20.68% [5]. Allegations - The complaint alleges that Revance made false or misleading statements and failed to disclose material breaches of the distribution agreement, which increased the risk of litigation and negatively impacted the tender offer [6].

Core Viewpoint - A class action lawsuit has been filed against Revance Therapeutics, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from February 29, 2024, to December 6, 2024, seeking damages for affected investors [1][6]. Company Overview - Revance Therapeutics is a biotechnology company focused on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications in the U.S. and internationally [3]. Legal Proceedings - The class action lawsuit is filed in the United States District Court for the Middle District of Tennessee, seeking to recover damages under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1]. - Investors who purchased Revance securities during the Class Period have until March 4, 2025, to request appointment as Lead Plaintiff [2]. Distribution Agreement - In January 2020, Revance entered into a distribution agreement with Teoxane SA, granting exclusive rights to market and distribute Teoxane's Resilient Hyaluronic Acid® dermal fillers in exchange for 2,500,000 shares of Revance common stock [4]. - Revance is obligated to meet minimum purchase and expenditure requirements, with potential termination rights for Teoxane in case of material breaches by Revance [4]. Merger Agreement - In August 2024, Revance announced a merger agreement with Crown Laboratories, with Crown proposing a tender offer to acquire all outstanding shares of Revance for $6.66 per share, totaling an enterprise value of $924 million [5]. Allegations in the Lawsuit - The lawsuit alleges that Revance made materially false and misleading statements regarding its business and operations, including being in material breach of the distribution agreement with Teoxane, which increased litigation risks and affected the tender offer [6]. - On September 23, 2024, Revance disclosed receiving a notice regarding alleged material breaches, leading to a delay in Crown's tender offer [7]. Stock Price Impact - Following the disclosure of the breach notice, Revance's stock price fell by $0.445 per share, or 7.66%, closing at $5.365 per share on September 23, 2024 [8]. - On December 9, 2024, Revance announced an amended merger agreement with Crown, reducing the tender offer price to $3.10 per share, a decrease of over 50% [8]. - This news led to a further decline in Revance's stock price by $0.79 per share, or 20.68%, closing at $3.03 per share on December 9, 2024 [9].

Core Viewpoint - A class action securities lawsuit has been filed against Revance Therapeutics, Inc. for alleged securities fraud affecting investors between February 29, 2024, and December 6, 2024 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Revance was in material breach of its Distribution Agreement with Teoxane, which granted exclusive rights to market and distribute Teoxane's dermal fillers [2] - Allegations include that this breach increased the risk of litigation and caused monetary and reputational harm to the company [2] - The lawsuit asserts that these issues led to the risk of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 4, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as a top securities litigation firm in the United States [4] - The firm has over 70 employees and extensive expertise in complex securities litigation [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Revance Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and material breaches related to a Distribution Agreement with Teoxane [1][2]. Group 1: Allegations - The complaint alleges that Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance exclusive rights to import, market, promote, sell, and distribute Teoxane's dermal fillers [1]. - The breach subjected the company to increased risks of litigation, monetary losses, and reputational harm [1]. - The allegations suggest that these issues increased the risk of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading [1]. Group 2: Class Action Details - The class period for the lawsuit is from February 29, 2024, to December 6, 2024 [1]. - Shareholders are encouraged to register for the class action by March 4, 2025, to potentially be appointed as lead plaintiffs [2]. - There is no cost or obligation for shareholders to participate in the case, and they will receive status updates through portfolio monitoring software [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - A class action lawsuit has been initiated against Revance Therapeutics, Inc. to recover losses for investors who acquired securities between February 29, 2024, and December 6, 2024 [1][2] Summary by Sections Lawsuit Details - The lawsuit alleges that Revance made false statements and concealed material breaches of a Distribution Agreement with Teoxane, which granted Revance exclusive rights to market and distribute Teoxane's dermal fillers [2] - The complaint claims that these actions increased the risk of litigation and monetary and reputational harm to the company [2] - It is also alleged that these issues raised the likelihood of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading [2] Investor Actions - Investors who incurred losses during the specified class period have until March 4, 2025, to apply to become the lead plaintiff in the lawsuit [3] - The lead plaintiff will represent all class members and can choose a law firm to litigate the case [3] - Participation as a lead plaintiff does not affect an investor's ability to share in any potential recovery from the lawsuit [3] Law Firm Information - Johnson Fistel, LLP is a recognized law firm specializing in shareholder rights and securities class action lawsuits, with offices in multiple states [4] - The firm represents both individual and institutional investors, including foreign investors who have purchased on US exchanges [4]

Core Viewpoint - A class action securities lawsuit has been filed against Revance Therapeutics, Inc. for alleged securities fraud affecting investors between February 29, 2024, and December 6, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Revance was in material breach of its Distribution Agreement with Teoxane, which granted it exclusive rights to market and distribute Teoxane's dermal fillers [2]. - The breach allegedly increased the risk of litigation and caused monetary and reputational harm to the company [2]. - The lawsuit also suggests that these issues raised the likelihood of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]. - The firm has over 20 years of experience in complex securities litigation and employs a team of more than 70 professionals [4].